This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Resolvin E1 (RvE1); resolvin D1 (RvD1); cyclooxygenase-2 (COX-2)	<p>Studies in mice suggest that resolvins could help treat inflammatory pain. In mouse models of chemically induced acute and chronic inflammatory pain, nanogram doses of RvE1 or RvD1 reduced pain, hyperalgesia and mechanical allodynia at least as effectively as microgram doses of morphine or a COX-2 inhibitor. Ongoing work includes testing the resolvins in models of neuropathic pain and chronic pain.</p> <p>Resolvix Pharmaceuticals Inc.'s RX-10045, an isopropyl ester prodrug of a synthetic RvE1 analog formulated as a topical solution, has completed Phase I/II testing to treat dry eye. Resolvix's RX-10001, an oral solution of synthetic RvE1, has completed Phase I testing to treat asthma, arthritis and inflammatory bowel disease. Resolvix has resolvin analogs in discovery research for multiple indications.</p> <p>SciBX 3(16); doi:10.1038/scibx.2010.504 Published online April 22, 2010</p>	Patent application filed by Brigham and Women's Hospital; available for licensing	<p>Xu, Z.-Z. <i>et al. Nat. Med.</i>; published online April 11, 2010; doi:10.1038/nm.2123</p> <p>Contact: Ru-Rong Ji, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. e-mail: rrji@zeus.bwh.harvard.edu</p> <p>Contact: Charles N. Serhan, same affiliation as above e-mail: cnserhan@zeus.bwh.harvard.edu</p>